Clinical trial drug offers hope for Alzheimer’s treatment

A drug currently in clinical trials is offering new hope for patients suffering from Alzheimer’s disease.

Dr. Frank Longo explained why the treatment could matter for one of the most difficult areas in medicine.

Alzheimer’s has historically been a tough market for drug development, with high failure rates and long trial timelines.

That is why any promising clinical-stage progress gets close attention from healthcare investors.

For biotech and pharma, Alzheimer’s remains one of the highest-risk but highest-impact treatment categories.